WINTON GROUP Ltd Takes $604,000 Position in Maravai LifeSciences Holdings, Inc. $MRVI

WINTON GROUP Ltd purchased a new stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 96,800 shares of the company’s stock, valued at approximately $604,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Royal Bank of Canada grew its position in Maravai LifeSciences by 49.0% in the 1st quarter. Royal Bank of Canada now owns 9,761 shares of the company’s stock worth $27,000 after purchasing an additional 3,209 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of Maravai LifeSciences during the 1st quarter worth approximately $37,000. R Squared Ltd lifted its position in shares of Maravai LifeSciences by 76.0% during the 1st quarter. R Squared Ltd now owns 27,394 shares of the company’s stock worth $78,000 after buying an additional 11,827 shares in the last quarter. Squarepoint Ops LLC purchased a new position in shares of Maravai LifeSciences in the 2nd quarter worth approximately $128,000. Finally, AXQ Capital LP boosted its stake in shares of Maravai LifeSciences by 63.8% in the 4th quarter. AXQ Capital LP now owns 43,994 shares of the company’s stock worth $143,000 after buying an additional 17,135 shares during the last quarter. 50.25% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on MRVI. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maravai LifeSciences in a research report on Wednesday, August 26th. Wells Fargo & Company boosted their price objective on Maravai LifeSciences from $5.50 to $6.50 and gave the stock an “overweight” rating in a research report on Friday, August 7th. UBS Group upped their price objective on Maravai LifeSciences from $2.50 to $8.00 and gave the company a “neutral” rating in a research note on Wednesday, September 9th. Finally, Wall Street Zen lowered Maravai LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 29th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $6.83.

Maravai LifeSciences Stock Performance

Shares of MRVI stock opened at $6.88 on Wednesday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.98 and a current ratio of 4.05. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of -13.23 and a beta of 0.60. Maravai LifeSciences Holdings, Inc. has a 52 week low of $2.55 and a 52 week high of $9.42. The firm’s 50-day simple moving average is $6.89 and its two-hundred day simple moving average is $5.11.

Maravai LifeSciences (NASDAQ:MRVI) last released its earnings results on Thursday, August 6th. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.02. Maravai LifeSciences had a negative net margin of 37.07% and a negative return on equity of 15.70%. The firm had revenue of $51.44 million during the quarter, compared to the consensus estimate of $48.67 million. As a group, equities analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.2 earnings per share for the current year.

Maravai LifeSciences Company Profile

Maravai LifeSciences, Inc (NASDAQ: MRVI) is a life sciences company that develops and supplies products and services used in biopharmaceutical research, drug development and manufacturing. Its offerings support the production and analysis of nucleic acids, including DNA and RNA used in applications such as messenger RNA therapeutics, vaccines, gene therapies and molecular diagnostics.

Through its nucleic acid production businesses, Maravai provides specialized enzymes, modified nucleotides, nucleoside triphosphates, oligonucleotides, capping products and related materials.